Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan–Meier Curves with Trial Sequential Analysis DOI Creative Commons
Youssef Soliman, Mohamed Abuelazm, Basma Ehab Amer

et al.

American Journal of Cardiovascular Drugs, Journal Year: 2024, Volume and Issue: 24(5), P. 629 - 640

Published: July 4, 2024

The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in managing cardiovascular outcomes patients with type diabetes mellitus (T2DM) is evolving. This meta-analysis seeks to explore the influence SGLT2i on recurrence atrial fibrillation (AF) following catheter ablation (CA) individuals T2DM qualitatively and quantitatively. A comprehensive literature search was conducted electronic databases. Studies meeting predefined criteria were included. Individual patient data (IPD) used from reconstructed time-to-event estimate hazard ratios (HRs) 95% confidence intervals for AF recurrence. IPD followed by a direct assess risk total five studies [one randomized controlled trial (RCT) four cohort studies] included this study, qualitative analysis, while comprising 1043 quantitative analysis. pooled Kaplan–Meier curve based showed significantly lower group compared all antidiabetic drugs (log-rank P = 0.00011) dipeptidyl-peptidase IV (DPP4i) 0.01). Cox regression analysis consistent results. Direct that SGLT2i, medications (HR 0.57, CI [0.44, 0.73], I2) DPP4i 0.41, [0.24, 0.70], I2), associated are reduced after CA T2DM. These results suggest promising improving clinical population.

Language: Английский

Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan–Meier Curves with Trial Sequential Analysis DOI Creative Commons
Youssef Soliman, Mohamed Abuelazm, Basma Ehab Amer

et al.

American Journal of Cardiovascular Drugs, Journal Year: 2024, Volume and Issue: 24(5), P. 629 - 640

Published: July 4, 2024

The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in managing cardiovascular outcomes patients with type diabetes mellitus (T2DM) is evolving. This meta-analysis seeks to explore the influence SGLT2i on recurrence atrial fibrillation (AF) following catheter ablation (CA) individuals T2DM qualitatively and quantitatively. A comprehensive literature search was conducted electronic databases. Studies meeting predefined criteria were included. Individual patient data (IPD) used from reconstructed time-to-event estimate hazard ratios (HRs) 95% confidence intervals for AF recurrence. IPD followed by a direct assess risk total five studies [one randomized controlled trial (RCT) four cohort studies] included this study, qualitative analysis, while comprising 1043 quantitative analysis. pooled Kaplan–Meier curve based showed significantly lower group compared all antidiabetic drugs (log-rank P = 0.00011) dipeptidyl-peptidase IV (DPP4i) 0.01). Cox regression analysis consistent results. Direct that SGLT2i, medications (HR 0.57, CI [0.44, 0.73], I2) DPP4i 0.41, [0.24, 0.70], I2), associated are reduced after CA T2DM. These results suggest promising improving clinical population.

Language: Английский

Citations

4